Andrew Reardon - Sep 23, 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
CLO & Secretary
Signature
/s/ Andrew Reardon
Stock symbol
LGND
Transactions as of
Sep 23, 2024
Transactions value $
-$94,661
Form type
4
Date filed
9/25/2024, 08:54 PM
Previous filing
Aug 30, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $105K +2K +8.88% $52.27 24.5K Sep 23, 2024 Direct
transaction LGND Common Stock Sale -$199K -2K -8.15% $99.60 22.5K Sep 23, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -2K -2.74% $0.00 70.9K Sep 23, 2024 Common Stock 2K $52.27 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter.